Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-08

AUTHORS

Annette C. Reboli, Coleman Rotstein, Daniel H. Kett, Michael Maschio, Shannon Cartier, Richard Chambers, Miriam Tarallo

ABSTRACT

Background: Candidaemia and other forms of invasive candidiasis (C/IC) are serious and costly events for hospitalized patients, particularly those in the ICU. Both fluconazole and the echinocandins are recommended as first-line therapy for C/IC. Resource use and cost considerations are important in selecting appropriate treatment but little information is available on the economic implications of using echinocandins in this setting.Objective: To compare resource utilization and treatment costs (in $US) associated with the echinocandin anidulafungin (200mg intravenously on day 1, then 100mg intravenously daily) versus those of fluconazole (800mg intravenously on day 1, then 400mg intravenously daily) as first-line treatment for C/IC.Methods: Available charts from patients enrolled in a recent clinical trial comparing anidulafungin and fluconazole for C/IC were reviewed. Patients who were in the ICU at study entry were identified, and the following data, collected during the 13-week study period, were compared between treatment groups: global response at end of study treatment, number of days patients survived after hospital discharge (‘hospital-free’ days), hospital resource use, and C/IC-related costs (year 2008 values) to a US hospital payer. These comparisons were also conducted for all non-ICU hospitalized patients, and for survivors in both study populations. Sensitivity analyses explored the cost impact of variability in the hospitalization costs between ICUs and non-ICU wards and of reduced duration intravenous therapy.Statistical comparisons between the two treatment groups were conducted for clinical outcomes, resource use and cost measures, using regression models. All statistical comparisons were adjusted for baseline co-variates (Acute Physiology and Chronic Health Evaluation [APACHE] II score, absolute neutrophil count and catheter removal status).Results: For ICU patients with C/IC (n = 63), global response was significantly higher for anidulafungin than fluconazole (68.6% vs 42.9%; p= 0.03). ICU patients treated with anidulafungin had an average of 13.9 more hospital-free days (18.2 vs 4.3 days; p = 0.04) than those treated with fluconazole. After adjustment for co-variates, although lower costs were observed for anidulafungin vs fluconazole in ICU patients and in ICU patients who survived, no statistical differences were found. For all hospitalized patients (n = 159), global response was also higher for anidulafungin (78.3% vs 60.5%; p < 0.01). There was no difference in average length of hospitalization (29.6 days) or hospital-free days. After adjustment for co-variates, anidulafungin treatment resulted in an incremental C/IC-related cost of $US2680 (p = 0.73). For hospitalized patients who survived (anidulafungin 81.9%, fluconazole 69.7%), anidulafungin treatment was associated with an incremental cost of $US231 (p = 0.98).Conclusion: Anidulafungin as first-line treatment of C/IC appears to be of particular benefit to ICU patients, improving clinical outcomes and possibly decreasing costs, driven by reduced ICU and hospital stay, when compared with fluconazole. Anidulafungin also yielded significantly improved treatment outcomes in the general inpatient population, with total costs similar to fluconazole. More... »

PAGES

705-717

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/11584810-000000000-00000

DOI

http://dx.doi.org/10.2165/11584810-000000000-00000

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031187530

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21591820


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anidulafungin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antifungal Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Candidemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Candidiasis, Invasive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase III as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Critical Illness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Echinocandins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluconazole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Resources", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospital Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospitalization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intensive Care Units", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Length of Stay", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Regression Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Medicine and Dentistry of New Jersey (UMDNJ)/Robert Wood Johnson Medical School, Camden, New Jersey, USA", 
          "id": "http://www.grid.ac/institutes/grid.430387.b", 
          "name": [
            "University of Medicine and Dentistry of New Jersey (UMDNJ)/Robert Wood Johnson Medical School, Camden, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reboli", 
        "givenName": "Annette C.", 
        "id": "sg:person.01147664000.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147664000.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Toronto, Toronto, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/grid.17063.33", 
          "name": [
            "University of Toronto, Toronto, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rotstein", 
        "givenName": "Coleman", 
        "id": "sg:person.01015727037.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015727037.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Miller School of Medicine at University of Miami, Miami, Florida, USA", 
          "id": "http://www.grid.ac/institutes/grid.26790.3a", 
          "name": [
            "Miller School of Medicine at University of Miami, Miami, Florida, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kett", 
        "givenName": "Daniel H.", 
        "id": "sg:person.0656500517.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656500517.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "i3 Innovus, Burlington, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "i3 Innovus, Burlington, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maschio", 
        "givenName": "Michael", 
        "id": "sg:person.01304324333.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304324333.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "i3 Innovus, Burlington, Ontario, Canada", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "i3 Innovus, Burlington, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cartier", 
        "givenName": "Shannon", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, New York, New York, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chambers", 
        "givenName": "Richard", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, New York, New York, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tarallo", 
        "givenName": "Miriam", 
        "id": "sg:person.01164305705.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164305705.85"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00134-008-1338-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010625321", 
          "https://doi.org/10.1007/s00134-008-1338-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10096-006-0159-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044049473", 
          "https://doi.org/10.1007/s10096-006-0159-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10096-004-1104-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049836714", 
          "https://doi.org/10.1007/s10096-004-1104-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-08", 
    "datePublishedReg": "2011-08-01", 
    "description": "Background: Candidaemia and other forms of invasive candidiasis (C/IC) are serious and costly events for hospitalized patients, particularly those in the ICU. Both fluconazole and the echinocandins are recommended as first-line therapy for C/IC. Resource use and cost considerations are important in selecting appropriate treatment but little information is available on the economic implications of using echinocandins in this setting.Objective: To compare resource utilization and treatment costs (in $US) associated with the echinocandin anidulafungin (200mg intravenously on day 1, then 100mg intravenously daily) versus those of fluconazole (800mg intravenously on day 1, then 400mg intravenously daily) as first-line treatment for C/IC.Methods: Available charts from patients enrolled in a recent clinical trial comparing anidulafungin and fluconazole for C/IC were reviewed. Patients who were in the ICU at study entry were identified, and the following data, collected during the 13-week study period, were compared between treatment groups: global response at end of study treatment, number of days patients survived after hospital discharge (\u2018hospital-free\u2019 days), hospital resource use, and C/IC-related costs (year 2008 values) to a US hospital payer. These comparisons were also conducted for all non-ICU hospitalized patients, and for survivors in both study populations. Sensitivity analyses explored the cost impact of variability in the hospitalization costs between ICUs and non-ICU wards and of reduced duration intravenous therapy.Statistical comparisons between the two treatment groups were conducted for clinical outcomes, resource use and cost measures, using regression models. All statistical comparisons were adjusted for baseline co-variates (Acute Physiology and Chronic Health Evaluation [APACHE] II score, absolute neutrophil count and catheter removal status).Results: For ICU patients with C/IC (n = 63), global response was significantly higher for anidulafungin than fluconazole (68.6% vs 42.9%; p= 0.03). ICU patients treated with anidulafungin had an average of 13.9 more hospital-free days (18.2 vs 4.3 days; p = 0.04) than those treated with fluconazole. After adjustment for co-variates, although lower costs were observed for anidulafungin vs fluconazole in ICU patients and in ICU patients who survived, no statistical differences were found. For all hospitalized patients (n = 159), global response was also higher for anidulafungin (78.3% vs 60.5%; p < 0.01). There was no difference in average length of hospitalization (29.6 days) or hospital-free days. After adjustment for co-variates, anidulafungin treatment resulted in an incremental C/IC-related cost of $US2680 (p = 0.73). For hospitalized patients who survived (anidulafungin 81.9%, fluconazole 69.7%), anidulafungin treatment was associated with an incremental cost of $US231 (p = 0.98).Conclusion: Anidulafungin as first-line treatment of C/IC appears to be of particular benefit to ICU patients, improving clinical outcomes and possibly decreasing costs, driven by reduced ICU and hospital stay, when compared with fluconazole. Anidulafungin also yielded significantly improved treatment outcomes in the general inpatient population, with total costs similar to fluconazole.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/11584810-000000000-00000", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "keywords": [
      "hospital-free days", 
      "first-line treatment", 
      "ICU patients", 
      "hospitalized patients", 
      "anidulafungin treatment", 
      "clinical outcomes", 
      "invasive candidiasis", 
      "treatment groups", 
      "non-ICU hospitalized patients", 
      "non-ICU wards", 
      "first-line therapy", 
      "general inpatient population", 
      "recent clinical trials", 
      "hospital resource use", 
      "cost of treatment", 
      "hospital payer", 
      "hospital stay", 
      "hospital discharge", 
      "study entry", 
      "intravenous therapy", 
      "day patients", 
      "study treatment", 
      "hospitalization costs", 
      "inpatient population", 
      "clinical trials", 
      "treatment outcomes", 
      "appropriate treatment", 
      "study population", 
      "patients", 
      "echinocandin anidulafungin", 
      "ICU", 
      "available charts", 
      "anidulafungin", 
      "incremental cost", 
      "fluconazole", 
      "study period", 
      "statistical difference", 
      "treatment costs", 
      "resource use", 
      "statistical comparison", 
      "treatment", 
      "candidaemia", 
      "candidiasis", 
      "therapy", 
      "outcomes", 
      "echinocandins", 
      "regression models", 
      "particular benefit", 
      "little information", 
      "average length", 
      "days", 
      "resource utilization", 
      "hospitalization", 
      "response", 
      "ICUs", 
      "stay", 
      "group", 
      "population", 
      "costly events", 
      "wards", 
      "survivors", 
      "trials", 
      "baseline", 
      "global response", 
      "cost impact", 
      "adjustment", 
      "differences", 
      "payers", 
      "total cost", 
      "use", 
      "economic implications", 
      "IC", 
      "setting", 
      "cost considerations", 
      "charts", 
      "period", 
      "discharge", 
      "comparison", 
      "sensitivity analysis", 
      "benefits", 
      "measures", 
      "utilization", 
      "events", 
      "entry", 
      "average", 
      "data", 
      "form", 
      "number", 
      "impact", 
      "end", 
      "variability", 
      "implications", 
      "cost", 
      "analysis", 
      "length", 
      "cost measures", 
      "information", 
      "consideration", 
      "model", 
      "low cost"
    ], 
    "name": "Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis", 
    "pagination": "705-717", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031187530"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/11584810-000000000-00000"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21591820"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/11584810-000000000-00000", 
      "https://app.dimensions.ai/details/publication/pub.1031187530"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_548.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/11584810-000000000-00000"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/11584810-000000000-00000'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/11584810-000000000-00000'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/11584810-000000000-00000'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/11584810-000000000-00000'


 

This table displays all metadata directly associated to this object as RDF triples.

321 TRIPLES      21 PREDICATES      153 URIs      142 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/11584810-000000000-00000 schema:about N0d5ad3ed2079422fa80848c4711b81b8
2 N1643b1e8c895422eab376c00d0c62679
3 N2f7853d2f9b443b0b386ba637aeb2d93
4 N418e4b8fccf647f2b37eeab67ecb7ae2
5 N456945d0dac6470f9c01afab545ea9d3
6 N617323821af94ab38128cbf304adcb37
7 N62f5b4bf8df748cdbf88bde66f25b4de
8 N6cd805a30cf0427c9cbae4594b1531d4
9 N799b32db4e154efca974ed86c2c3b924
10 N7f9ae5511a3648e7aa4b7e837841b5f6
11 N81ff61cb5acf497d8c55678765cb632d
12 N820b7a15964c408da5c17355e18d53f7
13 N8ca519f5350f40f4aba7275fbe534b7b
14 Nac9f5777ee6540adbf68533e5dfb31f3
15 Nb2f76067a48c46ccbe5a593eb352ce25
16 Nb664f379076e42bb846bb7a4051e8d4f
17 Nbdaca74a19e24f4eba7043ce29e4898f
18 Ndd0fcc13a3994ac3bd12833ec89dd035
19 Ne9796ab35e5a470c800a3b0e5abcbec6
20 Nee5f0ddc53fa43198be4cc2b8073b0fc
21 Nf4a1b69ee884442a8b9959ed713d6836
22 Nf6aa2220f8f44bd8b28cad18c0a5fb3d
23 Nf913e26df3d044cba9bc2bd1ac942e1a
24 Nff217b5e8bb742ee8ba785fce1696d51
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author N1b5e48385bc9414a84acb2b316b71877
28 schema:citation sg:pub.10.1007/s00134-008-1338-7
29 sg:pub.10.1007/s10096-004-1104-x
30 sg:pub.10.1007/s10096-006-0159-2
31 schema:datePublished 2011-08
32 schema:datePublishedReg 2011-08-01
33 schema:description Background: Candidaemia and other forms of invasive candidiasis (C/IC) are serious and costly events for hospitalized patients, particularly those in the ICU. Both fluconazole and the echinocandins are recommended as first-line therapy for C/IC. Resource use and cost considerations are important in selecting appropriate treatment but little information is available on the economic implications of using echinocandins in this setting.Objective: To compare resource utilization and treatment costs (in $US) associated with the echinocandin anidulafungin (200mg intravenously on day 1, then 100mg intravenously daily) versus those of fluconazole (800mg intravenously on day 1, then 400mg intravenously daily) as first-line treatment for C/IC.Methods: Available charts from patients enrolled in a recent clinical trial comparing anidulafungin and fluconazole for C/IC were reviewed. Patients who were in the ICU at study entry were identified, and the following data, collected during the 13-week study period, were compared between treatment groups: global response at end of study treatment, number of days patients survived after hospital discharge (‘hospital-free’ days), hospital resource use, and C/IC-related costs (year 2008 values) to a US hospital payer. These comparisons were also conducted for all non-ICU hospitalized patients, and for survivors in both study populations. Sensitivity analyses explored the cost impact of variability in the hospitalization costs between ICUs and non-ICU wards and of reduced duration intravenous therapy.Statistical comparisons between the two treatment groups were conducted for clinical outcomes, resource use and cost measures, using regression models. All statistical comparisons were adjusted for baseline co-variates (Acute Physiology and Chronic Health Evaluation [APACHE] II score, absolute neutrophil count and catheter removal status).Results: For ICU patients with C/IC (n = 63), global response was significantly higher for anidulafungin than fluconazole (68.6% vs 42.9%; p= 0.03). ICU patients treated with anidulafungin had an average of 13.9 more hospital-free days (18.2 vs 4.3 days; p = 0.04) than those treated with fluconazole. After adjustment for co-variates, although lower costs were observed for anidulafungin vs fluconazole in ICU patients and in ICU patients who survived, no statistical differences were found. For all hospitalized patients (n = 159), global response was also higher for anidulafungin (78.3% vs 60.5%; p < 0.01). There was no difference in average length of hospitalization (29.6 days) or hospital-free days. After adjustment for co-variates, anidulafungin treatment resulted in an incremental C/IC-related cost of $US2680 (p = 0.73). For hospitalized patients who survived (anidulafungin 81.9%, fluconazole 69.7%), anidulafungin treatment was associated with an incremental cost of $US231 (p = 0.98).Conclusion: Anidulafungin as first-line treatment of C/IC appears to be of particular benefit to ICU patients, improving clinical outcomes and possibly decreasing costs, driven by reduced ICU and hospital stay, when compared with fluconazole. Anidulafungin also yielded significantly improved treatment outcomes in the general inpatient population, with total costs similar to fluconazole.
34 schema:genre article
35 schema:isAccessibleForFree false
36 schema:isPartOf N078ba90438324538a5863c1db0e088eb
37 Nc7f1a1038aef4af899c0692aff25dfdc
38 sg:journal.1102812
39 schema:keywords IC
40 ICU
41 ICU patients
42 ICUs
43 adjustment
44 analysis
45 anidulafungin
46 anidulafungin treatment
47 appropriate treatment
48 available charts
49 average
50 average length
51 baseline
52 benefits
53 candidaemia
54 candidiasis
55 charts
56 clinical outcomes
57 clinical trials
58 comparison
59 consideration
60 cost
61 cost considerations
62 cost impact
63 cost measures
64 cost of treatment
65 costly events
66 data
67 day patients
68 days
69 differences
70 discharge
71 echinocandin anidulafungin
72 echinocandins
73 economic implications
74 end
75 entry
76 events
77 first-line therapy
78 first-line treatment
79 fluconazole
80 form
81 general inpatient population
82 global response
83 group
84 hospital discharge
85 hospital payer
86 hospital resource use
87 hospital stay
88 hospital-free days
89 hospitalization
90 hospitalization costs
91 hospitalized patients
92 impact
93 implications
94 incremental cost
95 information
96 inpatient population
97 intravenous therapy
98 invasive candidiasis
99 length
100 little information
101 low cost
102 measures
103 model
104 non-ICU hospitalized patients
105 non-ICU wards
106 number
107 outcomes
108 particular benefit
109 patients
110 payers
111 period
112 population
113 recent clinical trials
114 regression models
115 resource use
116 resource utilization
117 response
118 sensitivity analysis
119 setting
120 statistical comparison
121 statistical difference
122 stay
123 study entry
124 study period
125 study population
126 study treatment
127 survivors
128 therapy
129 total cost
130 treatment
131 treatment costs
132 treatment groups
133 treatment outcomes
134 trials
135 use
136 utilization
137 variability
138 wards
139 schema:name Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis
140 schema:pagination 705-717
141 schema:productId N3fcbd1afac794de092dba41c1fd0a351
142 N5a1af4a512044ba8b8bad442aa52ba81
143 Nd89cc3591a4f477fb3a7e6a310cb3e2c
144 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031187530
145 https://doi.org/10.2165/11584810-000000000-00000
146 schema:sdDatePublished 2022-11-24T20:54
147 schema:sdLicense https://scigraph.springernature.com/explorer/license/
148 schema:sdPublisher N621466114d9a4680a2bbe6f39777b334
149 schema:url https://doi.org/10.2165/11584810-000000000-00000
150 sgo:license sg:explorer/license/
151 sgo:sdDataset articles
152 rdf:type schema:ScholarlyArticle
153 N06f8321c3d6b40c194569866d72b7ce5 schema:affiliation grid-institutes:None
154 schema:familyName Cartier
155 schema:givenName Shannon
156 rdf:type schema:Person
157 N078ba90438324538a5863c1db0e088eb schema:volumeNumber 29
158 rdf:type schema:PublicationVolume
159 N0d5ad3ed2079422fa80848c4711b81b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Drug Costs
161 rdf:type schema:DefinedTerm
162 N12952526bf8c4d748f3f9aee190c0aa1 schema:affiliation grid-institutes:grid.410513.2
163 schema:familyName Chambers
164 schema:givenName Richard
165 rdf:type schema:Person
166 N1643b1e8c895422eab376c00d0c62679 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Antifungal Agents
168 rdf:type schema:DefinedTerm
169 N1b5e48385bc9414a84acb2b316b71877 rdf:first sg:person.01147664000.24
170 rdf:rest Ne71146cdae694436aed65a93bc507da0
171 N2d027c25873040cb8e1b96fc2849ac2c rdf:first sg:person.01304324333.33
172 rdf:rest Ncefbee407b244174869cebbb1542b71a
173 N2f7853d2f9b443b0b386ba637aeb2d93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Length of Stay
175 rdf:type schema:DefinedTerm
176 N3a845c0aada14c4b9fe889d044e5839f rdf:first sg:person.01164305705.85
177 rdf:rest rdf:nil
178 N3fcbd1afac794de092dba41c1fd0a351 schema:name doi
179 schema:value 10.2165/11584810-000000000-00000
180 rdf:type schema:PropertyValue
181 N418e4b8fccf647f2b37eeab67ecb7ae2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Clinical Trials, Phase III as Topic
183 rdf:type schema:DefinedTerm
184 N456945d0dac6470f9c01afab545ea9d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Candidiasis, Invasive
186 rdf:type schema:DefinedTerm
187 N5a1af4a512044ba8b8bad442aa52ba81 schema:name pubmed_id
188 schema:value 21591820
189 rdf:type schema:PropertyValue
190 N617323821af94ab38128cbf304adcb37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Middle Aged
192 rdf:type schema:DefinedTerm
193 N621466114d9a4680a2bbe6f39777b334 schema:name Springer Nature - SN SciGraph project
194 rdf:type schema:Organization
195 N62f5b4bf8df748cdbf88bde66f25b4de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Double-Blind Method
197 rdf:type schema:DefinedTerm
198 N6cd805a30cf0427c9cbae4594b1531d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Adult
200 rdf:type schema:DefinedTerm
201 N799b32db4e154efca974ed86c2c3b924 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Anidulafungin
203 rdf:type schema:DefinedTerm
204 N7f9ae5511a3648e7aa4b7e837841b5f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Hospitalization
206 rdf:type schema:DefinedTerm
207 N81ff61cb5acf497d8c55678765cb632d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Humans
209 rdf:type schema:DefinedTerm
210 N820b7a15964c408da5c17355e18d53f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Health Resources
212 rdf:type schema:DefinedTerm
213 N8ca519f5350f40f4aba7275fbe534b7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Female
215 rdf:type schema:DefinedTerm
216 Nac9f5777ee6540adbf68533e5dfb31f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Critical Illness
218 rdf:type schema:DefinedTerm
219 Nb2f76067a48c46ccbe5a593eb352ce25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Candidemia
221 rdf:type schema:DefinedTerm
222 Nb664f379076e42bb846bb7a4051e8d4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Echinocandins
224 rdf:type schema:DefinedTerm
225 Nb883d47bac03407db7fa937a168b9a9c rdf:first sg:person.0656500517.09
226 rdf:rest N2d027c25873040cb8e1b96fc2849ac2c
227 Nbdaca74a19e24f4eba7043ce29e4898f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Fluconazole
229 rdf:type schema:DefinedTerm
230 Nc7f1a1038aef4af899c0692aff25dfdc schema:issueNumber 8
231 rdf:type schema:PublicationIssue
232 Ncefbee407b244174869cebbb1542b71a rdf:first N06f8321c3d6b40c194569866d72b7ce5
233 rdf:rest Nd7204e68ba5b426abb5bff91369c086d
234 Nd7204e68ba5b426abb5bff91369c086d rdf:first N12952526bf8c4d748f3f9aee190c0aa1
235 rdf:rest N3a845c0aada14c4b9fe889d044e5839f
236 Nd89cc3591a4f477fb3a7e6a310cb3e2c schema:name dimensions_id
237 schema:value pub.1031187530
238 rdf:type schema:PropertyValue
239 Ndd0fcc13a3994ac3bd12833ec89dd035 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
240 schema:name Regression Analysis
241 rdf:type schema:DefinedTerm
242 Ne71146cdae694436aed65a93bc507da0 rdf:first sg:person.01015727037.87
243 rdf:rest Nb883d47bac03407db7fa937a168b9a9c
244 Ne9796ab35e5a470c800a3b0e5abcbec6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
245 schema:name Male
246 rdf:type schema:DefinedTerm
247 Nee5f0ddc53fa43198be4cc2b8073b0fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
248 schema:name Aged
249 rdf:type schema:DefinedTerm
250 Nf4a1b69ee884442a8b9959ed713d6836 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
251 schema:name Hospital Costs
252 rdf:type schema:DefinedTerm
253 Nf6aa2220f8f44bd8b28cad18c0a5fb3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
254 schema:name Intensive Care Units
255 rdf:type schema:DefinedTerm
256 Nf913e26df3d044cba9bc2bd1ac942e1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
257 schema:name Randomized Controlled Trials as Topic
258 rdf:type schema:DefinedTerm
259 Nff217b5e8bb742ee8ba785fce1696d51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
260 schema:name Retrospective Studies
261 rdf:type schema:DefinedTerm
262 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
263 schema:name Medical and Health Sciences
264 rdf:type schema:DefinedTerm
265 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
266 schema:name Clinical Sciences
267 rdf:type schema:DefinedTerm
268 sg:journal.1102812 schema:issn 1170-7690
269 1179-2027
270 schema:name PharmacoEconomics
271 schema:publisher Springer Nature
272 rdf:type schema:Periodical
273 sg:person.01015727037.87 schema:affiliation grid-institutes:grid.17063.33
274 schema:familyName Rotstein
275 schema:givenName Coleman
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015727037.87
277 rdf:type schema:Person
278 sg:person.01147664000.24 schema:affiliation grid-institutes:grid.430387.b
279 schema:familyName Reboli
280 schema:givenName Annette C.
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147664000.24
282 rdf:type schema:Person
283 sg:person.01164305705.85 schema:affiliation grid-institutes:grid.410513.2
284 schema:familyName Tarallo
285 schema:givenName Miriam
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164305705.85
287 rdf:type schema:Person
288 sg:person.01304324333.33 schema:affiliation grid-institutes:None
289 schema:familyName Maschio
290 schema:givenName Michael
291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304324333.33
292 rdf:type schema:Person
293 sg:person.0656500517.09 schema:affiliation grid-institutes:grid.26790.3a
294 schema:familyName Kett
295 schema:givenName Daniel H.
296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656500517.09
297 rdf:type schema:Person
298 sg:pub.10.1007/s00134-008-1338-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010625321
299 https://doi.org/10.1007/s00134-008-1338-7
300 rdf:type schema:CreativeWork
301 sg:pub.10.1007/s10096-004-1104-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1049836714
302 https://doi.org/10.1007/s10096-004-1104-x
303 rdf:type schema:CreativeWork
304 sg:pub.10.1007/s10096-006-0159-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044049473
305 https://doi.org/10.1007/s10096-006-0159-2
306 rdf:type schema:CreativeWork
307 grid-institutes:None schema:alternateName i3 Innovus, Burlington, Ontario, Canada
308 schema:name i3 Innovus, Burlington, Ontario, Canada
309 rdf:type schema:Organization
310 grid-institutes:grid.17063.33 schema:alternateName University of Toronto, Toronto, Ontario, Canada
311 schema:name University of Toronto, Toronto, Ontario, Canada
312 rdf:type schema:Organization
313 grid-institutes:grid.26790.3a schema:alternateName Miller School of Medicine at University of Miami, Miami, Florida, USA
314 schema:name Miller School of Medicine at University of Miami, Miami, Florida, USA
315 rdf:type schema:Organization
316 grid-institutes:grid.410513.2 schema:alternateName Pfizer Inc, New York, New York, USA
317 schema:name Pfizer Inc, New York, New York, USA
318 rdf:type schema:Organization
319 grid-institutes:grid.430387.b schema:alternateName University of Medicine and Dentistry of New Jersey (UMDNJ)/Robert Wood Johnson Medical School, Camden, New Jersey, USA
320 schema:name University of Medicine and Dentistry of New Jersey (UMDNJ)/Robert Wood Johnson Medical School, Camden, New Jersey, USA
321 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...